http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2337674-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8ee484f4ba9a0406b8927b5be6c4f2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9494c30f8f6cb9e15dc21e0d6895855 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
filingDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15f99e05e74eab6792b83e8ff9939c2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0885438f767d7bd0986ab9a1384c88b |
publicationDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2337674-C1 |
titleOfInvention | Method for accelerated optimisation of platelets activity in metabolic syndrome |
abstract | FIELD: medicine, hematology. n SUBSTANCE: method consists in long-term complex administration of low-calorie diet, 200 mg of labetalole twice a day, and 2 mg of lacidipine every morning, to correct platelet hemostasis in metabolic syndrome patients. The method allows primary hemostasis normalisation in metabolic syndrome patients during 2 months, due to ADP and ATP levels normalisation, as well as actin and myosin level and assemblage normalisation in platelets. n EFFECT: primary hemostasis normalisation in metabolic syndrome patients. n 1 ex |
priorityDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 235.